Angelina Osipyan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Angelina Osipyan has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Frank Jacobus Dekker
Chemical and Pharmaceutical Biology, Groningen Research Institute of Pharmacy (GRIP), University of Groningen, Antonius Deusinglaan 1, Groningen 9713 AV, The Netherlands
3 shared publications - Deng Chen
University of Groningen
2 shared publications Petra E. van der Wouden
Department of Chemical and Pharmaceutical Biology, Groningen Research Institute of Pharmacy, University of Groningen, 9713 AV, Groningen, The Netherlands
2 shared publicationsAbel Soto Gamez
Department of Biomedical Sciences of Cell & Systems Section Molecular Cell Biology University Medical Center Groningen University of Groningen Groningen 9712 CP The Netherlands
1 shared publication- Amalia Mihaela Dolga
Department of Molecular Pharmacology, Groningen Research Institute of Pharmacy (GRIP), Faculty of Science and Engineering, University of Groningen, Groningen, The Netherlands
1 shared publication Andrew J. Griffith
Department of Chemical and Pharmaceutical Biology Groningen Research Institute of Pharmacy (GRIP) University of Groningen Antonius Deusinglaan 1 Groningen 9713 AV The Netherlands
1 shared publication
Latest Publications
- Open Access
- 9 July 2024
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 276, 116665
The synthesis of 1,2,3-triazoles as binders of D-dopachrome tautomerase (D-DT) for the development of dual-targeting inhibitors
- 9 July 2024
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 276, 116665
Open AccessThe synthesis of 1,2,3-triazoles as binders of D-dopachrome tautomerase (D-DT) for the development of dual-targeting inhibitors
- Open Access
- 25 June 2024
- Published by Wiley in Advanced Science
- Vol. 11 (32) , e2403963
Small Molecule MIF Modulation Enhances Ferroptosis by Impairing DNA Repair Mechanisms
Ferroptosis is a form of regulated cell death that can be modulated by small molecules and has the potential for the development of therapeutics for oncology. Although excessive lipid peroxidation is the defining hallmark of ferroptosis, DNA damage may also play a significant role. In this study, a potential mechanistic role for MIF in homologous recombination (HR) DNA repair is identified. The inhibition or genetic depletion of MIF or other HR proteins, such as breast cancer type 1 susceptibility protein (BRCA1), is demonstrated to significantly enhance the sensitivity of cells to ferroptosis. The interference with HR results in the translocation of the tumor suppressor protein p53 to the mitochondria, which in turn stimulates the production of reactive oxygen species. Taken together, the findings demonstrate that MIF‐directed small molecules enhance ferroptosis via a putative MIF‐BRCA1‐RAD51 axis in HR, which causes resistance to ferroptosis. This suggests a potential novel druggable route to enhance ferroptosis by targeted anticancer therapeutics in the future.
- 25 June 2024
- Published by Wiley in Advanced Science
- Vol. 11 (32) , e2403963
Open AccessSmall Molecule MIF Modulation Enhances Ferroptosis by Impairing DNA Repair Mechanisms
Ferroptosis is a form of regulated cell death that can be modulated by small molecules and has the potential for the development of therapeutics for oncology. Although excessive lipid peroxidation is the defining hallmark of ferroptosis, DNA damage may also play a significant role. In this study, a potential mechanistic role for MIF in homologous recombination (HR) DNA repair is identified. The inhibition or genetic depletion of MIF or other HR proteins, such as breast cancer type 1 susceptibility protein (BRCA1), is demonstrated to significantly enhance the sensitivity of cells to ferroptosis. The interference with HR results in the translocation of the tumor suppressor protein p53 to the mitochondria, which in turn stimulates the production of reactive oxygen species. Taken together, the findings demonstrate that MIF‐directed small molecules enhance ferroptosis via a putative MIF‐BRCA1‐RAD51 axis in HR, which causes resistance to ferroptosis. This suggests a potential novel druggable route to enhance ferroptosis by targeted anticancer therapeutics in the future.
- Open Access
- 1 July 2021
- Published by Elsevier in Drug Discovery Today
- Vol. 26 (7) , 1728-1734
Epigenetic regulation in macrophage migration inhibitory factor (MIF)-mediated signaling in cancer and inflammation
- 1 July 2021
- Published by Elsevier in Drug Discovery Today
- Vol. 26 (7) , 1728-1734
Open AccessEpigenetic regulation in macrophage migration inhibitory factor (MIF)-mediated signaling in cancer and inflammation